MedTrace Logo

A Phase 1/2 Multicenter, Randomized, Study to Evaluate the Safety and Efficacy of VS101 Subconjunctival Latanoprost Insert in Subjects With Open-Angle Glaucoma or Ocular Hypertension

NCT02129673 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 77

Last updated 2018-03-14

No results posted yet for this study

Summary

Slow release formulation of latanoprost is compared for safety and pressure-lowering efficacy with topically administration of commercially available latanoprost in patient with glaucoma and ocular hypertension

Conditions

Interventions

DRUG

VS101 Insert Dose A

Sustained release of latanoprost into the eye

DRUG

VS101 Insert Dose B

Sustained release of latanoprost into the eye

DRUG

VS101 Insert Dose C

Sustained release of latanoprost into the eye

DRUG

Latanoprost 0.005% eye drops

Latanoprost 0.005% eye drops administered once daily on the eye

Sponsors & Collaborators

  • ViSci Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2017-05-31
Completion
2017-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02129673 on ClinicalTrials.gov